# Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

> **NCT00685776** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1623 (actual)

## Conditions studied

- Coronary Heart Disease (CHD)
- CHD Risk-Equivalent Disease

## Interventions

- **DRUG:** anacetrapib
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00685776
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-24
- **Primary completion:** 2009-07-02
- **Final completion:** 2017-11-23
- **Target enrollment:** 1623 (ACTUAL)
- **Last updated:** 2017-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00685776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00685776, "Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00685776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*